Aspirin backed as VTE therapy

Aspirin is a viable, simple alternative to lifelong warfarin therapy in patients who have had a first unprovoked venous thromboembolism, research finds.

An Australian-led trial found that switching patients onto aspirin, after a short period of anticoagulation, significantly reduced major vascular events compared to placebo, without increasing bleeding or adverse event rates.

Combined with another recent trial, the results suggest aspirin cuts rates of recurrent VTE by 32% and major vascular events by 34% compared to placebo, researchers wrote Sunday in the